Bisphosphonates in the Treatment of Osteoporosis

Endocrinology and Metabolism Clinics of North America

Volumn 41, Issue 3, 2012, Pages 487-506

  Diab, Dima L ^a   Watts, Nelson B ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b Mercy Health Osteoporosis and Bone Health Services   (United States)

Author keywords

Atrial fibrillation; Atypical femur fractures; Bisphosphonates; Drug holidays; Esophageal cancer; Long term safety; Osteonecrosis of the jaw; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; PLACEBO; RISEDRONIC ACID; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BLURRED VISION; BONE TURNOVER; BREAST CANCER; CANCER RISK; CONJUNCTIVITIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; ESOPHAGITIS; ESOPHAGUS CANCER; EYE PAIN; FEMUR FRACTURE; FEVER; FRAGILITY FRACTURE; GASTROINTESTINAL DISEASE; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HUMAN; HYPOCALCEMIA; IRITIS; JAW OSTEONECROSIS; KIDNEY CLEARANCE; MUSCULOSKELETAL PAIN; MYALGIA; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SCLERITIS; TREATMENT DURATION; TREATMENT PLANNING; UVEITIS; VERTEBRA FRACTURE;

ANTICARCINOGENIC AGENTS; ATRIAL FIBRILLATION; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG MONITORING; ESOPHAGEAL NEOPLASMS; FEMALE; FEMORAL FRACTURES; GASTROINTESTINAL DISEASES; HUMANS; MALE; MUSCULOSKELETAL PAIN; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; RISK ASSESSMENT; STROKE;

EID: 84864828251     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2012.04.007     Document Type: Review

References (123)

1. Watts N.B. Bisphosphonate treatment for osteoporosis. The osteoporotic syndrome 2000, 121-132. Academic Press, San Diego. L.V. Avioli (Ed.).
2. Russell R.G., Watts N.B., Ebetino F.H., et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008, (733):759.
3. Rogers M.J., Frith J.C., Luckman S.P., et al. Molecular mechanisms of action of bisphosphonates. Bone 1999, 24(5):73S-79S.
4. Bone H.G., Hosking D., Devogelaer J.P., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004, 350:1189-1199.
5. Black D.M., Schwartz A.V., Ensrud K.E., et al. Effects of continuing or stopping alendronate after 5 years of treatment. The Fracture Intervention Trial long-term extension (FLEX): a randomized trial. JAMA 2006, 296:2927-2938.
6. Wysowski D.K. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009, 360:89.
7. Wysowski D.K. Oral bisphosphonates and oesophageal cancer. BMJ 2010, 341:c4506.
8. Siris E.S., Oster M.W., Bilezikian J.P. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009, 360:1791. [author reply: 1791].
9. Shaheen N.J. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009, 360:1790.
10. Hofbauer L.C., Miehlke S. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009, 360:1790. [author reply: 1791].
11. Robins H.I., Holen K.D. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009, 360:1790. [author reply: 1791].
12. Abrahamsen B., Eiken P., Eastell R. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009, 360:1789. [author reply: 1791].
13. Solomon D.H., Patrick A., Brookhart M.A. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009, 360:1789.
14. Cardwell C.R., Abnet C.C., Cantwell M.M., et al. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010, 304:657.
15. Cardwell C.R., Abnet C.C., Veal P., et al. Exposure to oral bisphosphonates and risk of cancer. Int J Cancer 2011, [Epub ahead of print].
16. Green J., Czanner G., Reeves G., et al. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 2010, 341:c4444.
17. Ribeiro A., DeVault K.R., Wolfe J.T., et al. Alendronate-associated esophagitis: endoscopic and pathologic features. Gastrointest Endosc 1998, 47:525.
18. Abraham S.C., Cruz-Correa M., Lee L.A., et al. Alendronate-associated esophageal injury: pathologic and endoscopic features. Mod Pathol 1999, 12:1152.
19. Available at: . Accessed January 2012. http://www.fda.gov/Drugs/DrugSafety/ucm263320.htm.
20. Adami S., Bhalla A.K., Dorizzi R., et al. The acute phase response after bisphosphonate administration. Calcif Tissue Int 1987, 41:326-331.
21. Gallacher S.J., Ralston S.H., Patel U., et al. Side-effects of pamidronate. Lancet 1989, 2:42-43.
22. Zojer N., Keck A.V., Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf 1999, 21(5):389-406.
23. Maalouf N.M., Heller H.J., Odvina C.V., et al. Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature. Endocr Pract 2006, 12:48-53.
24. Fraunfelder F.W., Fraunfelder F.T. Bisphosphonates and ocular inflammation. N Engl J Med 2003, 348:1187.
25. Lewiecki E.M. Safety of long-term bisphosphonate therapy for the management of osteoporosis. Drugs 2011, 71:791.
26. Recker R.R., Lewiecki E.M., Miller P.D., et al. Safety of bisphosphonates in the treatment of osteoporosis. Am J Med 2009, 122:S22.
27. Miller P.D. Treatment of osteoporosis in chronic kidney disease and end-stage renal disease. Curr Osteoporos Rep 2005, 3:5.
28. Miller P.D., Roux C., Boonen S., et al. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 2005, 20:2105.
29. Jamal S.A., Bauer D.C., Ensrud K.E., et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the Fracture Intervention Trial. J Bone Miner Res 2007, 22:503.
30. Lyles K.W., Colon-Emeric C.S., Magaziner J.S., et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007, 357:1799.
31. Lewiecki E.M., Miller P.D. Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. Expert Opin Drug Saf 2007, 6:663.
32. Eisman J.A., Civitelli R., Adami S., et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 2008, 35:488.
33. Miller P.D., Ward P., Pfister T., et al. Renal tolerability of intermittent intravenous ibandronate treatment for patients with postmenopausal osteoporosis: a review. Clin Exp Rheumatol 2008, 26:1125.
34. Boonen S., Sellmeyer D.E., Lippuner K., et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int 2008, 74:641.
35. Miller P.D. Diagnosis and treatment of osteoporosis in chronic renal disease. Semin Nephrol 2009, 29:144.
36. Miller P.D. Is there a role for bisphosphonates in chronic kidney disease?. Semin Dial 2007, 20:186.
37. Miller P.D. The role of bone biopsy in patients with chronic renal failure. Clin J Am Soc Nephrol 2008, 3(Suppl 3):S140.
38. Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809.
39. Black D.M., Reid I.R., Boonen S., et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012, 27(2):243.
40. Cummings S.R., Schwartz A.V., Black D.M. Alendronate and atrial fibrillation. N Engl J Med 2007, 356:1895.
41. Karam R., Camm J., McClung M. Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med 2007, 357:712.
42. Heckbert S.R., Li G., Cummings S.R., et al. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 2008, 168:826.
43. Sorensen H.T., Christensen S., Mehnert F., et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 2008, 336:813.
44. Abrahamsen B., Eiken P., Brixen K. Atrial fibrillation in fracture patients treated with oral bisphosphonates. J Intern Med 2009, 265:581.
45. Bunch T.J., Anderson J.L., May H.T., et al. Relation of bisphosphonate therapies and risk of developing atrial fibrillation. Am J Cardiol 2009, 103:824.
46. Grosso A., Douglas I., Hingorani A., et al. Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis. PLoS One 2009, 4:e4720.
47. Loke Y.K., Jeevanantham V., Singh S. Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Saf 2009, 32:219.
48. Barrett-Connor E., Swern A.S., Hustad C.M., et al. Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials. Osteoporos Int 2012, 23:233.
49. Rhee C.W., Lee J., Oh S., et al. Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis. Osteoporos Int 2012, 23:247.
50. Available at: . Accessed January 2012. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm136201.htm.
51. Wysowski D.K., Chang J.T. Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med 2005, 165:346.
52. Haworth C.S., Selby P.L., Webb A.K., et al. Oral corticosteroids and bone pain after pamidronate in adults with cystic fibrosis. Lancet 1999, 353:1886.
53. Haworth C.S., Selby P.L., Webb A.K., et al. Severe bone pain after intravenous pamidronate in adult patients with cystic fibrosis. Lancet 1998, 352:1753.
54. Available at: . Accessed January 2012. http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm124165.htm.
55. Khosla S., Burr D., Cauley J., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007, 22:1479.
56. Woo S.B., Hellstein J.W., Kalmar J.R. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006, 206(144):753-761.
57. Triester N., Woo S.-B. Bisphosphonate-associated osteonecrosis of the jaw. N Engl J Med 2006, 335:2348.
58. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003, 61:1115-1117. [letter].
59. Ruggiero S.L., Mehrotra B., Rosenberg T.J., et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004, 62:527-534.
60. Bilezikian J.P. Osteonecrosis of the jaw: do bisphosphonates pose a risk?. N Engl J Med 2006, 355:2278-2282.
61. Black D.M., Boonen S., Cauley J., et al. Effect of once-yearly infusion of zoledronic acid 5 mg on spine and hip fracture reduction in postmenopausal women with osteoporosis: the HORIZON pivotal fracture trial. J Bone Miner Res 2006, 21(Suppl 1):S16. [abstract].
62. IMS HEALTH. NPA Plus May 2006.
63. Agarwala S., Sule A., Pai B.U., et al. Alendronate in the treatment of avascular necrosis of the hip. Rheumatology 2002, 41(3):346-347.
64. Desai M.M., Sonone S., Bhasme V. Efficacy of alendronate in the treatment of avascular necrosis of the hip. Rheumatology 2005, 44(10):1331-1332.
65. Jeffcoat M.K. Safety of oral bisphosphonates: controlled studies on alveolar bone. Int J Oral Maxillofac Surg 2006, 21:349-353.
66. Palomo L., Bissada N.F., Liu J. Periodontal assessment of postmenopausal women receiving risedronate. Menopause 2005, 12:685-690.
67. Kolata G. Drug for bones is newly linked to jaw disease. New York Times 2006.
68. Rubin R. Drug linked to death of jawbone. USA Today 2005.
69. Knox R. Side effects noted with bone-loss drugs. National Public Radio, broadcast 2006. Available at: . http://www.npr.org/templates/story/story.php?storyId=5358285.
70. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007, 65:369-376.
71. Hellstein J.W., Adler R.A., Edwards B., et al. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 2011, 142:1243.
72. Osteoporosis medications and your dental health. J Am Dent Assoc 2011, 142:1320.
73. Visekruna M., Wilson D., McKiernan F.E. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 2008, 93:2948.
74. Mashiba T., Hirano T., Turner C.H., et al. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000, 15(4):613-620.
75. Odvina C.V., Zerwekh J.E., Rao D.S., et al. Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab 2005, 90(3):1294-1301.
76. Armamento-Villareal R., Napoli N., Diemer K., et al. Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif Tissue Int 2009, 85:37-44.
77. Imai K., Yamamoto S., Anamizu Y., et al. Pelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapy. J Bone Miner Metab 2007, 25:333.
78. Kwek E.B., Goh S.K., Koh J.S., et al. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?. Injury 2008, 39:224.
79. Lee P., Seibel M.J. More on atypical fractures of the femoral diaphysis. N Engl J Med 2008, 359:317. [author reply: 317].
80. Lee P., van der Wall H., Seibel M.J. Looking beyond low bone mineral density: multiple insufficiency fractures in a woman with post-menopausal osteoporosis on alendronate therapy. J Endocrinol Invest 2007, 30:590.
81. Lenart B.A., Lorich D.G., Lane J.M. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008, 358:1304.
82. Odvina C.V., Levy S., Rao S., et al. Unusual mid-shaft fractures during long term bisphosphonate therapy. Clin Endocrinol (Oxf) 2010, 72(2):161-168.
83. Schneider J.P. Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics 2009, 61:31-33.
84. Armamento-Villareal R., Napoli N., Panwar V., et al. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med 2009, 355:2048-2050.
85. Capeci C.M., Tejwani N.C. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am 2009, 91:2556.
86. Goh S.K., Yang K.Y., Koh J.S., et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007, 89:349.
87. Lenart B.A., Neviaser A.S., Lyman S., et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009, 20:1353.
88. Neviaser A.S., Lane J.M., Lenart B.A., et al. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008, 22:346.
89. Abrahamsen B., Eiken P., Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009, 24:1095.
90. Park-Wyllie L.Y., Mamdani M.M., Juurlink D.N., et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011, 305:783.
91. Shane E., Burr D., Ebeling P.R., et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010, 25:2267.
92. Feldstein A., Black D., Perrin N., et al. Incidence and demography of femur fractures with and without atypical features. J Bone Miner Res 2012, 27:977-986.
93. Maravic M., Ostertag A., Cohen-Solal M. Subtrochanteric/femoral shaft versus hip fractures: Incidences and identification of risk factors. J Bone Miner Res 2011, [Epub ahead of print].
94. Available at: . Accessed January 2012. http://www.fda.gov/drugs/drugsafety/ucm229009.htm.
95. Kuehn B.M. Long-term risks of bisphosphonates probed. JAMA 2009, 301:710.
96. Solomon D.H., Rekedal L., Cadarette S.M. Osteoporosis treatments and adverse events. Curr Opin Rheumatol 2009, 21:363.
97. Kennel K.A., Drake M.T. Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc 2009, 84:632-637.
98. Clezardin P. Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class. Bone 2011, 48:71.
99. Daniele G., Giordano P., De Luca A., et al. Anticancer effect of bisphosphonates: new insights from clinical trials and preclinical evidence. Expert Rev Anticancer Ther 2011, 11:299.
100. Chlebowski R.T. Bisphosphonates and breast cancer incidence and recurrence. Breast Dis 2011, 33(2):93-101.
101. Chlebowski R.T., Chen Z., Cauley J.A., et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 2010, 28:3582.
102. Chlebowski R.T., Col N. Bisphosphonates and breast cancer prevention. Anticancer Agents Med Chem 2012, 12:144.
103. Dreyfuss J.H. Oral bisphosphonate use associated with a decreased risk of breast cancer. CA Cancer J Clin 2010, 60:343.
104. Gnant M. Can oral bisphosphonates really reduce the risk of breast cancer in healthy women?. J Clin Oncol 2010, 28:3548.
105. Newcomb P.A., Trentham-Dietz A., Hampton J.M. Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer 2010, 102:799.
106. Rennert G., Pinchev M., Rennert H.S. Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 2010, 28:3577.
107. Vestergaard P., Fischer L., Mele M., et al. Use of bisphosphonates and risk of breast cancer. Calcif Tissue Int 2011, 88:255.
108. Rennert G., Pinchev M., Rennert H.S., et al. Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol 2011, 29:1146.
109. Kang J.H., Keller J.J., Lin H.C. A population-based 2-year follow-up study on the relationship between bisphosphonates and the risk of stroke. Osteoporos Int 2012, [Epub ahead of print].
110. Lu P.Y., Hsieh C.F., Tsai Y.W., et al. Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate. Clin Ther 2011, 33:1173.
111. Vestergaard P., Schwartz K., Pinholt E.M., et al. Stroke in relation to use of raloxifene and other drugs against osteoporosis. Osteoporos Int 2011, 22:1037.
112. Hartle J.E., Tang X., Kirchner H.L., et al. Bisphosphonate therapy, death, and cardiovascular events among female patients with CKD: a retrospective cohort study. Am J Kidney Dis 2012, 59(5):636-644.
113. Center J.R., Bliuc D., Nguyen N.D., et al. Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endocrinol Metab 2011, 96:1006.
114. Sambrook P.N., Cameron I.D., Chen J.S., et al. Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study. Osteoporos Int 2011, 22:2551.
115. Beaupre L.A., Morrish D.W., Hanley D.A., et al. Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos Int 2011, 22:983.
116. Watts N.B., Chines A., Olszynski W.P., et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 2008, 19:365-372.
117. Mellström D.D., Sörensen O.H., Goemaere S., et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004, 75(6):462-468.
118. Schwartz A.V., Bauer D.C., Cauley J.A., et al. Efficacy of continued alendronate for fractures in women without prevalent vertebral fracture: the FLEX trial (abstract). J Bone Miner Res 2007, 22(Suppl 1):S16-S17.
119. Eastell R., Hannon R.A., Wenderoth D., et al. Effect of stopping risedronate after long-term treatment on bone turnover. J Clin Endocrinol Metab 2011, 96:3367.
120. Papapoulos S.E., Cremers S.C. Prolonged bisphosphonate release after treatment in children. N Engl J Med 2007, 356:1075-1076.
121. Available at: . Accessed January 2012. http://www.fda.gov/AdvisoryCommittees/Calendar/ucm262477.htm.
122. Available at: . Accessed January 2012. http://media.aace.com/press-release/aace-responds-fda-hearing-bisphosphonates.
123. Compston J.E., Bilezikian J.P. Bisphosphonate therapy for osteoporosis: the long and short of it. J Bone Miner Res 2012, 27:240.